Lead Product(s): Cenobamate
Therapeutic Area: Neurology Product Name: Xcopri
Highest Development Status: Approved Product Type: Small molecule
Deal Size: $822.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 15, 2020
Proceeds will be used accelerate further advancement of the Company's pipeline which include, cenobamate, solriamfetol and among others.